Emcure Pharmaceuticals Limited has successfully completed its postal ballot voting process, with all three special resolutions for independent director re-appointments passed by the requisite majority. The pharmaceutical company announced the results on March 24, 2026, following a comprehensive remote e-voting process that concluded on March 20, 2026.

Regulatory Filing and Compliance

The company submitted its formal intimation to stock exchanges under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The filing confirmed that members approved the re-appointment of three independent directors through the postal ballot process, with all appointments taking effect as scheduled.

Director Re-appointment Details

The postal ballot process resulted in the successful re-appointment of three independent directors for their second terms. Each director brings specialized expertise to the board and has been confirmed as not debarred by SEBI or related to existing directors or key managerial personnel.

Voting Process and Results

The remote e-voting process was conducted from February 19 to March 20, 2026, under the supervision of scrutinizer Ashwini Inamdar from Mehta & Mehta, Company Secretaries. With 189,572,547 outstanding shares and 117,430 eligible shareholders, the voting demonstrated strong shareholder confidence in the board composition.

Resolution Performance Summary

All three resolutions achieved the required three-fourth majority as mandated under the Companies Act, 2013, and SEBI regulations. The promoter group showed unanimous support across all resolutions, while public institutional and non-institutional shareholders also demonstrated strong backing for the appointments.

Corporate Governance Compliance

The postal ballot was conducted in full compliance with Section 108 of the Companies Act, 2013, and Regulation 44 of SEBI Listing Regulations. Public notices were issued in Financial Express and Loksatta newspapers on February 18, 2026, ensuring transparency and regulatory adherence.

The company has uploaded the complete voting results and scrutinizer's report on its website at www.emcure.com and submitted all required documentation to NSE and BSE for regulatory compliance. Company Secretary Amruta Yangalwar signed the regulatory filing, confirming the completion of all procedural requirements.

Emcure Pharmaceuticals Limited has issued a clarification to BSE Limited regarding the recent significant increase in its share volume, stating that the movement is entirely market-driven and outside the company's control.

BSE Query and Company Response

The clarification came in response to BSE's email dated March 10, 2026, which sought explanation for the notable increase in trading volume of the company's shares. The exchange's surveillance department had flagged the unusual activity under reference number L/SURV/ONL/PV/APJ/2025-2026/961.

Regulatory Compliance Statement

Emcure Pharmaceuticals emphasized its commitment to regulatory compliance, confirming that there are no undisclosed events or information that require disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company assured that it remains aware of its disclosure obligations and has consistently ensured timely disclosure of all material events and information.

Key Points from the Clarification

The pharmaceutical company highlighted several important aspects in its response:

• The price and volume increase is market-driven and beyond company control
• No material events currently require disclosure under SEBI Listing Regulations
• The company maintains strict adherence to disclosure timelines
• Commitment to continue transparent reporting of future material events

Company Leadership

The clarification was signed by Amruta Yangalwar, Company Secretary and Compliance Officer (Membership Number: A25687), who digitally authenticated the document on March 10, 2026. The response demonstrates the company's proactive approach to addressing regulatory queries and maintaining transparency with stock exchanges and investors.